In our latest webinar, a number of expert practitioners discussed the latest findings of the use of 2.5% iPAAG (ArthramidVet) and upcoming advances.
EquiManagement has summarised the webinar in their blog below, which covers the latest findings on the use of 2.5% iPAAG (ArthramidVet®) for joint treatment, the mechanism of action, its treatment success rates, timeframe for success, and upcoming research.
Read the full article by EquiManagement HERE
This article was Posted by Stephanie L. Church, Editor-in-Chief | Jan 1, 2020 | 2019 NEAEP Symposium, Arthritis & Degenerative Joint Disease, Arthritis & Degenerative Joint Disease, Article, Horse Care,…
Dr Emma Wood has been in the racing industry most of her life but was a late bloomer to the veterinary world. She has been an assistant trainer both…
ArthramidVet® and the NZVA offered an exclusive opportunity to hear from the esteemed Dr Lisa Fortier who, alongside Dr Jason Lowe, discussed Intra-Articular Approaches to Osteoarthritis, a general topic that…
